{"title":"卵巢癌筛查的可行性。","authors":"Miyo K Chatanaka, Eleftherios P Diamandis","doi":"","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>The majority of the high-grade serous ovarian cancer (HGSOC) cases are diagnosed late, preventing effective treatment and therapy. We examine the feasibility of using EVA (Early oVArian cancer), a new molecular test for early HGSOC detection.</p><p><strong>Methods: </strong>Comparison of the advantages and disadvantages of EVA with previously reported ovarian cancer tests, including CA125, was made, and the positive and negative predictive values of the tests were calculated as a measure of usefulness in the clinic.</p><p><strong>Results: </strong>The positive predictive value of EVA and CA125 was 8.6% and 6.8% respectively, which was calculated based on the disease prevalence of 0.5%. The negative predictive value was 99.9% in both cases.</p><p><strong>Conclusions: </strong>EVA and CA125 are unlikely to provide a meaningful population screening method for HGSOC in women at risk, since the predictive values would drive women not to perform these tests.</p>","PeriodicalId":37192,"journal":{"name":"Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine","volume":"35 2","pages":"132-135"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380147/pdf/","citationCount":"0","resultStr":"{\"title\":\"The Feasibility for Screening for Ovarian Cancer.\",\"authors\":\"Miyo K Chatanaka, Eleftherios P Diamandis\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>The majority of the high-grade serous ovarian cancer (HGSOC) cases are diagnosed late, preventing effective treatment and therapy. We examine the feasibility of using EVA (Early oVArian cancer), a new molecular test for early HGSOC detection.</p><p><strong>Methods: </strong>Comparison of the advantages and disadvantages of EVA with previously reported ovarian cancer tests, including CA125, was made, and the positive and negative predictive values of the tests were calculated as a measure of usefulness in the clinic.</p><p><strong>Results: </strong>The positive predictive value of EVA and CA125 was 8.6% and 6.8% respectively, which was calculated based on the disease prevalence of 0.5%. The negative predictive value was 99.9% in both cases.</p><p><strong>Conclusions: </strong>EVA and CA125 are unlikely to provide a meaningful population screening method for HGSOC in women at risk, since the predictive values would drive women not to perform these tests.</p>\",\"PeriodicalId\":37192,\"journal\":{\"name\":\"Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine\",\"volume\":\"35 2\",\"pages\":\"132-135\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-08\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11380147/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/8/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q2\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Electronic Journal of the International Federation of Clinical Chemistry and Laboratory Medicine","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/8/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}
Introduction: The majority of the high-grade serous ovarian cancer (HGSOC) cases are diagnosed late, preventing effective treatment and therapy. We examine the feasibility of using EVA (Early oVArian cancer), a new molecular test for early HGSOC detection.
Methods: Comparison of the advantages and disadvantages of EVA with previously reported ovarian cancer tests, including CA125, was made, and the positive and negative predictive values of the tests were calculated as a measure of usefulness in the clinic.
Results: The positive predictive value of EVA and CA125 was 8.6% and 6.8% respectively, which was calculated based on the disease prevalence of 0.5%. The negative predictive value was 99.9% in both cases.
Conclusions: EVA and CA125 are unlikely to provide a meaningful population screening method for HGSOC in women at risk, since the predictive values would drive women not to perform these tests.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
